Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and Cost of High-Frequency IGRT in Elderly Stage III Non-Small-Cell Lung Cancer Patients

Samuel P Heilbroner, Eric P Xanthopoulos, Donna Buono, Daniel Carrier, Ben Y Durkee, Michael Corradetti, Tony JC Wang, Alfred I Neugut, Dawn L Hershman, Simon K Cheng
doi: https://doi.org/10.1101/2020.12.01.20241794
Samuel P Heilbroner
aDepartment of Radiation Oncology, New York Presbyterian Hospital, 622 W 168th St, New York, NY 10032
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric P Xanthopoulos
aDepartment of Radiation Oncology, New York Presbyterian Hospital, 622 W 168th St, New York, NY 10032
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donna Buono
bHerbert Irving Comprehensive Cancer Center, 1130 St Nicholas Ave, New York, NY 10032
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Carrier
aDepartment of Radiation Oncology, New York Presbyterian Hospital, 622 W 168th St, New York, NY 10032
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben Y Durkee
cDepartment of Radiation Oncology, University of Wisconsin–Madison, 600 Highland Avenue K4/334-3684, Madison, WI 53792
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Corradetti
dDuke Cancer Center, 3404 Wake Forest Rd, Raleigh, NC 27609
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tony JC Wang
aDepartment of Radiation Oncology, New York Presbyterian Hospital, 622 W 168th St, New York, NY 10032
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred I Neugut
bHerbert Irving Comprehensive Cancer Center, 1130 St Nicholas Ave, New York, NY 10032
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dawn L Hershman
bHerbert Irving Comprehensive Cancer Center, 1130 St Nicholas Ave, New York, NY 10032
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon K Cheng
aDepartment of Radiation Oncology, New York Presbyterian Hospital, 622 W 168th St, New York, NY 10032
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sc2335@cumc.columbia.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background High-frequency image-guided radiotherapy (hfIGRT) is ubiquitous but its benefits are unproven. We examined the cost effectiveness of hfIGRT in stage III non-small-cell lung cancer (NSCLC).

Methods We selected stage III NSCLC patients ≥66 years old who received definitive radiation therapy from the Surveillance, Epidemiology, and End-Results-Medicare database. Patients were stratified by use of hfIGRT using Medicare claims. Predictors for hfIGRT were calculated using a logistic model. The impact of hfIGRT on lung toxicity free survival (LTFS), esophageal toxicity free survival (ETFS), cancer-specific survival (CSS), overall survival (OS), and cost of treatment was calculated using Cox regressions, propensity score matching, and bootstrap methods.

Results Of the 4,430 patients in our cohort, 963 (22%) received hfIGRT and 3,468 (78%) did not. By 2011, 49% of patients were receiving hfIGRT. Predictors of hfIGRT use included treatment with intensity-modulated radiotherapy (IMRT) (OR = 7.5, p < 0.01), recent diagnosis (OR = 51 in 2011 versus 2006, p < 0.01), and residence in regions where the Medicare intermediary allowed IMRT (OR = 1.50, p < 0.01). hfIGRT had no impact on LTFS (HR 0.97; 95% CI 0.86 – 1.09), ETFS (HR 1.05; 95% CI 0.93–1.18), CSS (HR 0.94; 95% CI 0.84 – 1.04), or OS (HR 0.95; 95% CI 0.87 – 1.04). Mean radiotherapy and total medical costs six months after diagnosis were $17,330 versus $15,024 (p < 0.01) and $71,569 versus $69,693 (p = 0.49), respectively.

Conclusion hfIGRT did not affect clinical outcomes in elderly patients with stage III NSCLC but did increase radiation cost.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors would like to endorse the following potential conflicts of interest: Dr. Wang reports personal fees and non-financial support from AbbVie, non-financial support from Merck, personal fees from AstraZeneca, personal fees from Doximity, personal fees and non-financial support from Novocure, personal fees and non-financial support from Elekta and personal fees from Wolters Kluwer, outside the submitted work; Dr. Cheng reports consulting fees from AbbVie. The other authors have no conflicts of interest.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Columbia University Medical Center IRB approval was granted.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

This study makes use of the SEER-Medicare database, which is publically available through the NIH.

  • Abbreviations

    CBCT
    Cone-beam Computer Tomography
    CI
    Confidence Interval
    CSS
    Cancer-specific Survival
    ETFS
    Esophageal Toxicity Free Survival
    hfIGRT
    High-frequency Image Guided Radiation Therapy
    IMRT
    Intensity-modulated Radiotherapy
    LCDs
    Local Coverage Determinations
    LTFS
    Lung Toxicity Free Survival
    NSCLC
    Non-small-cell Lung Cancer
    OR
    Odds Ratios
    OS
    Overall Survival
    SEER-Medicare
    Surveillance, Epidemiology, And End-Results-Medicare
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted December 02, 2020.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Efficacy and Cost of High-Frequency IGRT in Elderly Stage III Non-Small-Cell Lung Cancer Patients
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Efficacy and Cost of High-Frequency IGRT in Elderly Stage III Non-Small-Cell Lung Cancer Patients
    Samuel P Heilbroner, Eric P Xanthopoulos, Donna Buono, Daniel Carrier, Ben Y Durkee, Michael Corradetti, Tony JC Wang, Alfred I Neugut, Dawn L Hershman, Simon K Cheng
    medRxiv 2020.12.01.20241794; doi: https://doi.org/10.1101/2020.12.01.20241794
    Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Citation Tools
    Efficacy and Cost of High-Frequency IGRT in Elderly Stage III Non-Small-Cell Lung Cancer Patients
    Samuel P Heilbroner, Eric P Xanthopoulos, Donna Buono, Daniel Carrier, Ben Y Durkee, Michael Corradetti, Tony JC Wang, Alfred I Neugut, Dawn L Hershman, Simon K Cheng
    medRxiv 2020.12.01.20241794; doi: https://doi.org/10.1101/2020.12.01.20241794

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Oncology
    Subject Areas
    All Articles
    • Addiction Medicine (70)
    • Allergy and Immunology (168)
    • Anesthesia (50)
    • Cardiovascular Medicine (448)
    • Dentistry and Oral Medicine (80)
    • Dermatology (55)
    • Emergency Medicine (157)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
    • Epidemiology (5219)
    • Forensic Medicine (3)
    • Gastroenterology (195)
    • Genetic and Genomic Medicine (750)
    • Geriatric Medicine (77)
    • Health Economics (212)
    • Health Informatics (694)
    • Health Policy (352)
    • Health Systems and Quality Improvement (223)
    • Hematology (99)
    • HIV/AIDS (162)
    • Infectious Diseases (except HIV/AIDS) (5823)
    • Intensive Care and Critical Care Medicine (356)
    • Medical Education (102)
    • Medical Ethics (25)
    • Nephrology (80)
    • Neurology (758)
    • Nursing (43)
    • Nutrition (129)
    • Obstetrics and Gynecology (141)
    • Occupational and Environmental Health (231)
    • Oncology (475)
    • Ophthalmology (149)
    • Orthopedics (38)
    • Otolaryngology (94)
    • Pain Medicine (39)
    • Palliative Medicine (19)
    • Pathology (139)
    • Pediatrics (223)
    • Pharmacology and Therapeutics (136)
    • Primary Care Research (96)
    • Psychiatry and Clinical Psychology (854)
    • Public and Global Health (1995)
    • Radiology and Imaging (345)
    • Rehabilitation Medicine and Physical Therapy (157)
    • Respiratory Medicine (283)
    • Rheumatology (93)
    • Sexual and Reproductive Health (72)
    • Sports Medicine (75)
    • Surgery (108)
    • Toxicology (25)
    • Transplantation (29)
    • Urology (39)